Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

摘要: The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in human cancer since it contributes to number of highly relevant processes tumor development and progression, including cell proliferation, regulation apoptotic death, angiogenesis metastatic spread. Among variety approaches used target EGFR signaling, blocking monoclonal antibodies small molecular weight tyrosine kinase compounds have been successfully developed. results large body preclinical studies clinical trials suggest that targeting the could represent significant contribution therapy. Both types agent exert antiproliferative activity when alone or combination with conventional antitumor treatments, such as chemotherapy radiation Although advanced drugs demonstrates their efficacy some diseases, lung, head neck colorectal cancers, issue constitutive resistance patients acquired responders remains an unexplored subject investigation. Recent evidence suggests specific activating mutations within domain explain dramatic responses molecule inhibitors subgroup lung patients. However, intrinsic mechanisms these are still unclear. This review will focus on findings therapeutic agents.